Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the efficacy of an 0.7 mg intravitreal dexamethasone
implant (Ozurdex®) on macular leakage and visual acuity for patients with recalcitrant
diabetic macular edema.